Literature DB >> 30559210

Innate and adaptive immunity combined for cancer treatment.

Sebastian Kobold1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30559210      PMCID: PMC6347723          DOI: 10.1073/pnas.1820166116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

Review 1.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

2.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Can we use interleukin-1β blockade for lung cancer treatment?

Authors:  Adrian Gottschlich; Stefan Endres; Sebastian Kobold
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 4.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

5.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Authors:  Irena Kaplanov; Yaron Carmi; Rachel Kornetsky; Avishai Shemesh; Galina V Shurin; Michael R Shurin; Charles A Dinarello; Elena Voronov; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-13       Impact factor: 11.205

6.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci.

Authors:  Sally A DuPré; Doug Redelman; Kenneth W Hunter
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

7.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Angela Dispenzieri; Morie A Gertz; Thomas E Witzig; Shaji Kumar; Suzanne R Hayman; Stephen J Russell; Francis K Buadi; Susan M Geyer; Megan E Campbell; Robert A Kyle; S Vincent Rajkumar; Philip R Greipp; Michael P Kline; Yuning Xiong; Laurie L Moon-Tasson; Kathleen A Donovan
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

8.  Targeting interleukin-22 for cancer therapy.

Authors:  Anamarija Markota; Stefan Endres; Sebastian Kobold
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

Review 9.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

10.  Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

Authors:  David Crossman; Alexander M K Rothman
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 3.005

View more
  2 in total

Review 1.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

2.  Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.

Authors:  Peter Libby; Sebastian Kobold
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.